NCT04616443View on ClinicalTrials.gov

OH2 Injection in Combination With HX008 for Melanoma.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Melanoma
Interventions
BIOLOGICAL

OH2 injection

Oncolytic Type 2 Herpes Simplex Virus

BIOLOGICAL

HX008 injection

Recombinant humanized anti-PD-1 monoclonal antibody of injection

Trial Locations (1)

100010

RECRUITING

Peking University Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Binhui Biopharmaceutical Co., Ltd.

INDUSTRY